Xcovery to Present at the AACR Annual Meeting 2016 Palm Beach Gardens, Fla., and Needham, Mass., April 12, 2016 – Xcovery, a developer of targeted therapeutics for cancer, today announced that Christine Lovly, MD, PhD, Assistant Professor of Medicine, Division of Hematology‐Oncology at the Vanderbilt University School of Medicine will present a poster titled “Phase I/II trial of X‐396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non‐small cell lung cancer (NSCLC)” at the American Association for Cancer Research (AACR) Annual Meeting 2016. The presentation details are as follows: Session Title: Phase II/III Clinical Trials in Progress Session Date and Time: Tuesday, April 19, 2016 from 8:00am ‐ 12:00pm CDT Session Location: Ernest N. Morial Convention Center in New Orleans, Louisiana: Convention Center, Halls G‐J, Poster Section 13 Poster Board Number: 16 Permanent Abstract Number: CT088 About X‐396 Xcovery’s lead asset is X‐396, a small molecule, anaplastic lymphoma kinase (ALK) inhibitor. It is being studied in the Xalt2 Study, a phase II trial for the treatment of ALK‐positive non‐small cell lung cancer (NSCLC). X‐396 also is being studied to treat patients with lymphoma and neuroblastoma. X‐396 has been validated in potency and selectivity assays that demonstrate it is more selective and up to 10 times more potent than competitive ALK inhibitors tested. The Xalt2 Study is currently enrolling patients. To learn more, visit: www.xalt2study.com or ClinicalTrials.gov under trial identifier NCT01625234. About Non‐Small Cell Lung Cancer and ALK Lung cancer is the second most common type of cancer identified in the United States with an estimated 221,000 new diagnoses expected in 2015. Non‐small cell lung cancer is the most common type of lung cancer, accounting for an estimated 85‐90% of the lung cancer cases. The anaplastic lymphoma kinase (ALK) gene is located on chromosome 2 and rearrangement of the ALK gene can lead to its activation or expression therefore increasing a person’s chance of certain types of cancer, including NSCLC. Between three and seven percent of patients with NSCLC have the ALK rearrangement making this a molecular target warranting investigation for NSCLC patients. About Xcovery Xcovery is a biopharmaceutical company working to improve the lives of patients with cancer by discovering medicines to fight advanced tumors. Xcovery is developing a pipeline of oncology therapies to target a wide range of advanced tumors. For more information, visit www.xcovery.com. Forward‐Looking Statements This press release contains forward‐looking statements that are based on company management’s current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected. ### Company Contact: Mike Webb Xcovery President and Chief Executive Officer (857) 202‐3911 mike@xcovery.com Media Contact: Julia Ogier MacDougall Biomedical Communications (781) 235‐3060 jogier@macbiocom.com